A first test of the pill AO-252 in people with advanced solid tumors, including tumors that spread to the brain
Original title: A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early safety test in people, and the right dose is still unknown.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing a new pill called AO-252 to see if it is safe and what dose is best.
Who this trial is for. This trial is for people with advanced solid tumors. Some have tumors that spread to the brain, and some do not. It tests a pill called AO-252.
Where it stands. This trial has not reported results. It is measuring how safe the pill is, how well people handle it, and how well it works. It is also looking for the best dose to use in later studies. Those answers are not in yet.
What this means, and what it doesn't
What it could mean: This is the first time this pill is being tried in people. Someone who fits might ask their care team about it. A care team can say if a study like this makes sense for one person.
What it doesn't mean: This does not mean the pill works. A trial is a test, not a proven treatment. Being in one is not a guarantee that it will help. It is not a promise of a cure.
Source: ClinicalTrials.gov, August 17, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.